A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants
NCT05818709
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
61
Enrollment
INDUSTRY
Sponsor class
Conditions
Facial Volume Deficit
Interventions
DEVICE:
HAC 22L
Sponsor
AbbVie